The FDA has approved a once-daily, extended-release oral suspension of methylphenidate (Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid formulation of the drug to be marketed for once-daily use. A short-acting oral solution (Methylin, and generics) has been available since 2003.1

METHYLPHENIDATE — All methylphenidate products are schedule II controlled substances. Short-acting methylphenidate is effective for treatment of ADHD, but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing. Long-acting methylphenidate preparations with once-daily dosing have therefore become the mainstay of clinical practice. Most long-acting formulations are available only as tablets or capsules and many children find these difficult to swallow. ... more      

Would you like to read the rest of this article?  Gain access below.